Metastasis of Breast Cancer

Al-Rawi, Mahir A.; Jiang, Wen Guo

doi:10.1007/978-1-4020-5867-7

Cited by 10 publications

(2 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall survival rate for primary metastatic breast cancer has constantly improved at a rate of 1% -2% yearly as shown in published analyses. The reason for this development seems to be the establishment of new therapy options [12,[14][15][16]. Thus, based on the current published data, patients survived longer in the last decade than in the earlier period [17].…”

Section: Discussionmentioning

confidence: 99%

“…Approximately 6% of all breast cancer patients test positive for metastatic disease at the time of their first diagnosis [11][12][13]. The incidence rate of this disease has persisted over the last 20 years [14]. The aim of the current retrospective study was to analyse the development of the median survival time over a fixed period and determine the underlying causes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of Survival in Patient with Primary Metastatic Breast Cancer over a 10-Year Periode: Prospective Analyses Based on Individual Patient Date from a Multicenter Data Bank

Barinoff¹,

Heitz²,

Küemmel³

et al. 2013

JCT

View full text Add to dashboard Cite

Approximately 6% of patients with breast cancer have distant metastases at the time of the initial diagnosis. The aim of this analysis was to examine the overall survival rate over time and to investigate the effect of new therapy options. Methods: This retrospective analysis was performed based on the data bank of the Clinic for Gynaecological Oncology/ Dr. Horst Schmidt Klinik, Wiesbaden and the Clinic for Gynaecological Oncology and Senology/Kliniken Essen Mitte, Essen. The patients with primary metastatic breast cancer (pmBC) who were diagnosed and treated at the accredited breast cancer centres of these clinics were enrolled between 1998 and 2007. The date of diagnosis was used to define 2 specifically chosen 5-year periods: 1998-2002 and 2003-2007. The follow-up time was on average 76 months. The Breslow Test was used to evaluate changes in the median survival time and to detect factors associated with the increase in survival rates. Results: Two hundred sixteen patients with complete baselines were analysed. Ninety patients were diagnosed between 1998 and 2002, and 126 patients received their diagnosis of pmBC between 2003 and 2007. The tumour-biological factors were the same in both groups, whereas the therapeutic concepts were different-the later group (2003-2007) received more aromatase inhibitors, taxane-based chemotherapy and trastuzumab. This finding resulted in an increased median survival time from 31 months in the years 1998-2002 to 44 months in the group with the first diagnosis between 2003 and 2007. Conclusions: Primary metastatic breast cancer occurred at constant rates over last 10 years. The tumour findings did not change in the time between the two examined groups; however, the treatment options in the 2003-2007 group included newly approved therapies. The time period of the first diagnosis was detected as a risk factor for overall survival. Those patients diagnosed in the more recent time frame had a significantly improved survival rate. The establishment of new therapy options may explain this finding.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Improvement of Survival in Patient with Primary Metastatic Breast Cancer over a 10-Year Periode: Prospective Analyses Based on Individual Patient Date from a Multicenter Data Bank

Barinoff¹,

Heitz²,

Küemmel³

et al. 2013

JCT

View full text Add to dashboard Cite

show abstract

Metastatic and triple-negative breast cancer: challenges and treatment options

Al-Mahmood

Sapiezynski

Garbuzenko

et al. 2018

Drug Deliv. and Transl. Res.

396

258

View full text Add to dashboard Cite

The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing biological drugs, targeted treatment and gene therapy can potentially reduce the mortality and improve the quality of life in patients with MBC. However, combination of several types of treatment is usually recommended. Triple negative breast cancer (TNBC) accounts for 10–20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). Consequently, convenient treatments used for MBC that target these receptors are not effective for TNBC which therefore requires special treatment approaches. This review discusses the occurrence of MBC, the prognosis and predictive biomarkers of MBC, and focuses on the novel advanced tactics for treatment of MBC and TNBC. Nanotechnology-based combinatorial approach for the suppression of EGFR by siRNA and gifitinib is described.

show abstract